Neuroscientific Biopharmaceuticals [ASX: NSB]
Biotechnology
Early Clinical Results Poised to Instil Investor Confidence
We update Neuroscientific Biopharmaceuticals (ASX: NSB) with a revised target price of $0.43, representing a 341% upside from the current share price of $0.10. As part of this update, we have refined our valuation framework to better reflect the unique characteristics of the StemSmart™ program. Traditional biotechnology valuation approaches are typically calibrated around small molecules or monoclonal antibodies, where market assumptions rely on established biologic pricing benchmarks and treatment paradigms. In contrast, mesenchymal stem cell (MSC) therapies represent a fundamentally different therapeutic modality, with distinct clinical positioning, pricing dynamics, and commercial adoption pathways. Accordingly, we have developed a dedicated bottom-up market model for MSC therapy in refractory Crohn’s disease, designed to better capture the potential commercial opportunity, expected launch dynamics, and the scale of early adoption required to generate meaningful revenues.
Importantly, the assumptions embedded in our model remain deliberately very conservative. We assume initial market penetration of only 0.1% of the refractory Crohn’s population in year one following launch, increasing to 0.5% and 1% in years two and three, respectively, corresponding to just 325 patients treated in year one in the base case. Despite these modest assumptions, the model still generates significant early revenue potential, reflecting the unmet medical need for patients with refractory Crohn's Disease. Our pricing assumptions also reflect the premium typically associated with advanced cell therapies. Recent commercial launches in regenerative medicine, including programs developed by Mesoblast, demonstrate that cell-based therapies can command substantial pricing premiums relative to traditional biologics, particularly in the US market, where reimbursement frameworks support high-value treatments for severe and refractory diseases. In our view, this analysis highlights the asymmetric upside embedded in the current valuation, with the company’s shares trading materially below the level implied by even conservative commercial assumptions, particularly in light of the recent positive data read-out from the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).
Promising Clinical Results Provide Confidence in Probability of Success for Phase 2 Clinical Trials
NSB announced promising clinical results for the initial cohort of patients enrolled in the TGA SAS program for fistulising Crohn’s disease. Although it is just the first set of results from the TGA SAS program, it informs us of the efficacy and validates the probability of success that StemSmartTM may achieve during the Phase 2 clinical trials, expected to commence towards the end of 2026. Furthermore, the company has entered into a partnership with Q-Gen, one of Australia’s largest cell therapy manufacturers, with decades of experience supporting the development of treatments. It is currently in the demonstration runs stage, where Q-Gen must manufacture consecutive batches of compliant StemSmartTM MSCs, with TGA approval and full-scale manufacturing expected in H2 2026. The company announced results from the clinical study evaluating StemSmartTM in patients experiencing complications post-kidney transplantation, indicating that the MSC therapy may be a viable candidate for treating diseases beyond Crohn’s disease. Overall, these major developments substantially advance the company’s program within the formal clinical development pathway, positioning it to generate the pivotal data required to support regulatory submissions and, if successful, enable global commercialisation of its novel, patented MSC therapy.
Strengthened Management Team and A New Clinical and Scientific Advisory Board Boost NSB’s Commercialisation Prospects
Beyond clinical outcomes, the company has also strengthened its operational and clinical teams by appointing a new Chief Executive Officer (CEO) and a Chief Medical Officer (CMO). Apart from changes in management, NSB has also established a new clinical and scientific advisory board composed of experienced medical professionals across the potential target markets in which the company can address with its patented StemSmartTM technology. This newly formed board is expected to inform and guide NSB as the company develops its product and progresses through various clinical trials for the use of its patented technology to treat Crohn’s disease, Graft-versus-Host Disease (GvHD), lung diseases, and kidney transplantation.